Drug profile · INN
brodalumab
KYNTHEUM
brodalumab (KYNTHEUM) is a interleukin-17 receptor a antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — brodalumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
brodalumab (KYNTHEUM) is a interleukin-17 receptor a antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-17 receptor A antagonist
Primary target: Interleukin-17 receptor A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is brodalumab?
brodalumab (KYNTHEUM) is a interleukin-17 receptor a antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for brodalumab?
KYNTHEUM is a marketed brand name for brodalumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brodalumab?
brodalumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.